Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1544508

USP

Piroxicam

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H13N3O4S
Número de CAS:
36322-90-4
Peso molecular:
331.35
Número MDL:
MFCD00057317
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750878
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

piroxicam

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

Clave InChI

QYSPLQLAKJAUJT-UHFFFAOYSA-N

Información sobre el gen

human ... PTGS1(5742) , PTGS2(5743)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Piroxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Piroxicam Capsules
  • Piroxicam Compounded Cream
  • Piroxicam Compounded Oral Suspension

Acciones bioquímicas o fisiológicas

Cyclooxygenase inhibitor.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

P2130000

Piroxicam, European Pharmacopoeia (EP) Reference Standard

Y0001475

Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard

BP463

Piroxicam, British Pharmacopoeia (BP) Reference Standard

1544541

Piroxicam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1544574

Piroxicam Related Compound G, United States Pharmacopeia (USP) Reference Standard

1544600

Piroxicam Related Compound J, United States Pharmacopeia (USP) Reference Standard

1544520

Piroxicam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1544519

2-Aminopyridine, United States Pharmacopeia (USP) Reference Standard

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palabra de señalización

Danger

Frases de peligro

H301,H373

Clasificaciones de peligro

Acute Tox. 3 Oral - STOT RE 2 Oral

Órganos de actuación

Gastrointestinal tract

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

D Gerber
Drug intelligence & clinical pharmacy, 21(9), 707-710 (1987-09-01)
During the approximately five years (1981-86) that piroxicam has been available in South Africa, the Medicines Safety Centre has received 31 reports of adverse reactions associated with this drug. Among these are two reactions not previously recorded in the literature
P Pfitzenmeyer et al.
The Journal of rheumatology, 21(8), 1573-1577 (1994-08-01)
We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured
R E Lister et al.
European journal of rheumatology and inflammation, 12(4), 6-11 (1993-01-01)
Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with
C R Lee et al.
Drugs, 48(6), 907-929 (1994-12-01)
Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard
R N Brogden et al.
Drugs, 28(4), 292-323 (1984-10-01)
Piroxicam is a chemically different non-steroidal anti-inflammatory drug with a long half-life which enables it to be administered once daily. This member of the oxicam series of compounds is now well established in the treatment of rheumatoid arthritis and osteoarthritis
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico